What does this research mean for the field?

In patients with Parkinson's disease, istradefylline is associated with reduced mortality and treatment escalation, but an increased risk of fractures, compared to catechol-O-methyltransferase (COMT) inhibitors. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

synapse

⌘+K

synapse

⌘+K

March 3, 2026Open Access

Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study

Key Points

Istradefylline is linked to lower mortality rates compared to catechol-O-methyltransferase inhibitors, suggesting improved survival outcomes overall.
Patients on istradefylline had lower treatment escalation rates, indicating easier management of their condition and reduced medication changes over time.

Structured PICO

Does istradefylline improve outcomes compared to COMT inhibitors in patients with Parkinson's disease?

Population

Patients with Parkinson's disease

Intervention

Istradefylline

Comparator

Catechol-O-methyltransferase (COMT) inhibitors

Outcome

Mortality, treatment escalation, and fracture riskhard clinical

In a real-world cohort of Parkinson's disease patients, istradefylline was associated with lower mortality and less treatment escalation but a higher risk of fractures compared to COMT inhibitors.

Abstract

Istradefylline was associated with reduced mortality and treatment escalation but increased fracture risk compared with COMT inhibitors, supporting further evaluation of adenosine A2A antagonists.

Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study

Key Points

Structured PICO

Abstract

Cite This Study